Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-β1 and MMPs

Clinical and Experimental Metastasis

Volumn 18, Issue 4, 2000, Pages 343-352

  Zhang, H ^a   Morisaki, T ^a   Matsunaga, H ^a   Sato, N ^a   Uchiyama, A ^a   Hashizume, K ^a   Nagumo, F ^a   Tadano, J ^a   Katano, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Invasiveness; Matrix metalloproteinases; PSK; Transforming growth factor 1; Urokinase plasminogen activator

Indexed keywords

GELATINASE A; GELATINASE B; KRESTIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CELL VIABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; STOMACH CANCER;

ADJUVANTS, IMMUNOLOGIC; ANTIBIOTICS, ANTINEOPLASTIC; CELL ADHESION; CELL DIVISION; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LAMININ; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEOGLYCANS; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 0034955586     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Tumor invasion and metastasis: An imbalance of positive and negative regulation
2. Transforming growth factor-beta: Recent progress and new challenges
3. Stable overexpression of TGF-beta 1 in a transitional carcinoma cell line: Impact on fibronectin production
4. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma
5. Transforming growth factor-beta 1 (TGF-beta 1) is a preoperative prognostic indicator in advanced gastric carcinoma
6. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma
7. The effect of thrombospondin-1 and TGF-betal on pancreatic cancer cell invasion
8. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B
9. Type IV collagenases in invasive tumors
10. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-beta 1 (Ser223, 225)
11. Krestin (PSK)
12. Adjuvant therapy of gastric cancer: The Japanese experience
13. Antitumor effect of oral administration of PSK in tumor-bearing mice and rat
14. Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice
15. Indication of immunochemotherapy using PSK for gastric cancer from the standpoint of host factors and studies of antitumor effect and PSK mechanism
16. Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential
17. Potentiation of cytotoxicity of mitomycin C by a polyacetylenic alcohol, Panaxytoriol
18. A rapid in vitro assay for quantitating the invasive potential of tumor cells
19. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production
20. Prostaglandin protects against taurocholate-induced damage to rat gastric mucosal cell culture
21. Transforming growth factor beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro
22. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
23. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
24. Human transforming growth factor-beta complementary, DNA sequence and expression in normal and transformed cells
25. Molecular cloning of cDNA coding for human preprourokinase
26. cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by HepG2 hepatoma cell
27. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
28. Defining the invasive phenotype of proximal gastric cancer cell
29. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta
30. Antitumor effect of intratumoral administration of a coriolus preparation, PSK: Inhibition of tumor invasion in vitro
31. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: An overview
32. Antimetastatic effect of PSK, a protein-bound polysaccharide, against the B16-BL6 mouse melanoma
33. Ambidextrous effect of PSK on motilities of both macrophages and tumor cells
34. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes
35. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness
36. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by upregulating urokinase activity
37. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis
38. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines
39. Oral administration of PSK can improve the impaired anti-tumor CD4+T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice
40. Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: Possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K
41. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-beta
42. Plasmin, substilisin-like endoproteases, tissue plasminogen activator, and urokinase plasminogen activator are involved in activation of latent TGF-beta1 in human seminal plasma
43. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer
44. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer